PL2693216T3 - Sposób diagnozowania lub wstępnego diagnozowania beta-amyloidopatii - Google Patents
Sposób diagnozowania lub wstępnego diagnozowania beta-amyloidopatiiInfo
- Publication number
- PL2693216T3 PL2693216T3 PL13190419T PL13190419T PL2693216T3 PL 2693216 T3 PL2693216 T3 PL 2693216T3 PL 13190419 T PL13190419 T PL 13190419T PL 13190419 T PL13190419 T PL 13190419T PL 2693216 T3 PL2693216 T3 PL 2693216T3
- Authority
- PL
- Poland
- Prior art keywords
- amyloidopathy
- prediagnosis
- diagnosis
- beta
- Prior art date
Links
- 238000003745 diagnosis Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
- C07D279/28—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom with other substituents attached to the ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
- C07D279/14—1,4-Thiazines; Hydrogenated 1,4-thiazines condensed with carbocyclic rings or ring systems
- C07D279/18—[b, e]-condensed with two six-membered rings
- C07D279/22—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom
- C07D279/24—[b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Biochemistry (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE102010044561 | 2010-09-07 | ||
| EP11755294.3A EP2614060B1 (de) | 2010-09-07 | 2011-08-30 | Thiethylperazin zur behandlung einer beta-amyloidopathie oder alpha-synucleopathie |
| EP13190419.5A EP2693216B1 (de) | 2010-09-07 | 2011-08-30 | Verfahren zur Diagnose oder Prädiagnose einer Beta-Amyloidopathie |
| PCT/EP2011/064893 WO2012031941A2 (de) | 2010-09-07 | 2011-08-30 | 2-(R²-THIO)-10-[3-(4-R1-PIPERAZIN-1-YL)PROPYL]-10H-PHENOTHIAZINE ZUR BEHANDLUNG EINER β-AMYLOIDOPATHIE ODER ALPHA-SYNUCLEOPATHIE SOWIE VERFAHREN ZU DEREN DIAGNOSE ODER PRÄDIAGNOSE |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2693216T3 true PL2693216T3 (pl) | 2019-04-30 |
Family
ID=44645670
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11755294T PL2614060T3 (pl) | 2010-09-07 | 2011-08-30 | Tietyloperazyna do leczenia β-amyloidopatii lub α-synukleinopatii |
| PL13190419T PL2693216T3 (pl) | 2010-09-07 | 2011-08-30 | Sposób diagnozowania lub wstępnego diagnozowania beta-amyloidopatii |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11755294T PL2614060T3 (pl) | 2010-09-07 | 2011-08-30 | Tietyloperazyna do leczenia β-amyloidopatii lub α-synukleinopatii |
Country Status (13)
| Country | Link |
|---|---|
| US (3) | US20130184268A1 (pl) |
| EP (3) | EP2614060B1 (pl) |
| JP (2) | JP6084924B2 (pl) |
| CN (2) | CN103237802B (pl) |
| BR (1) | BR112013005472A2 (pl) |
| CA (2) | CA2870626C (pl) |
| DE (2) | DE102010062810B4 (pl) |
| DK (2) | DK2693216T3 (pl) |
| ES (2) | ES2605705T3 (pl) |
| MX (1) | MX357521B (pl) |
| PL (2) | PL2614060T3 (pl) |
| RU (2) | RU2016118021A (pl) |
| WO (1) | WO2012031941A2 (pl) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20230628T1 (hr) | 2016-07-25 | 2023-09-29 | Wista Laboratories Ltd. | Primjena i doziranje diaminofenotiazina |
| PT3826639T (pt) | 2018-07-26 | 2024-10-09 | Wista Lab Ltd | Dosagem otimizada de diaminofenotiazinas em populações |
| US20230192748A1 (en) * | 2020-03-16 | 2023-06-22 | Doublerainbow Biosciences Inc. | Etoposide Glycosides, Methods Of Making, And Uses Thereof As An Anti-Cancer Drug |
| EP4460311A1 (en) * | 2022-01-04 | 2024-11-13 | Immungenetics AG | Specific dosage of phenothiazine compounds for use in treatment or prevention of alzheimer's dementia |
| JP2025537481A (ja) * | 2022-10-18 | 2025-11-18 | イムヌジェネティクス アーゲー | アルツハイマー型認知症に罹患している又はアルツハイマー型認知症を発症する危険性のある対象の特定 |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH365379A (de) * | 1956-04-18 | 1962-11-15 | Sandoz Ag | Verfahren zur Herstellung von neuen, in 3-Stellung mit einer einwertigen Schwefelfunktion substituierten Phenothiazinen |
| BE568701A (pl) * | 1957-06-18 | |||
| US3621097A (en) * | 1970-03-30 | 1971-11-16 | Jan Marcel Didier Aron Samuel | Method and compositions for treatment of mental illness |
| US4471116A (en) * | 1982-07-28 | 1984-09-11 | Hoffmann-La Roche Inc. | Substituted (10H-phenothiazin-10-L)-propyl-1-piperazines |
| US6566368B2 (en) * | 1994-04-22 | 2003-05-20 | Pentech Pharmaceuticals, Inc. | Apomorphine-containing dosage form for ameliorating male erectile dysfunction |
| EP0778773A1 (en) * | 1994-08-08 | 1997-06-18 | Albert Einstein College Of Medicine Of Yeshiva University | Methods for treating and/or preventing alzheimer's disease using phenothiazines and/or thioxanthenes |
| DE4430091A1 (de) * | 1994-08-25 | 1996-02-29 | Bayer Ag | Verwendung von N-substituierten Phenothiazinen |
| PT1470818E (pt) * | 2003-04-25 | 2006-11-30 | Neuro3D | Utilização de derivados de fenotiazina piperazina no fabrico de um medicamento com efeitos neuroprotectores e/ou neurotróficos no cns e/ou pns |
| DE102005014142B4 (de) * | 2005-03-23 | 2006-11-09 | Hennig Arzneimittel Gmbh & Co. Kg | Pelletförmige Retardzubereitung gegen Schwindel |
| WO2007062862A2 (en) * | 2005-12-02 | 2007-06-07 | Ludwig Maximilians Universität München | Use of calmodulin inhibitors for the treatment of neurodegenerative disorders |
| EP2457904B1 (en) * | 2006-07-11 | 2014-11-19 | Wista Laboratories Ltd. | Methods of synthesis and/or purification of diaminophenothiazinium compounds |
| JP5244810B2 (ja) * | 2006-11-10 | 2013-07-24 | カラ セラピューティクス インコーポレイテッド | 合成ペプチドアミド |
| GB0701970D0 (en) * | 2007-02-01 | 2007-03-14 | Wilson Stuart | Treatment of protein aggregation diseases |
| WO2008133884A2 (en) * | 2007-04-23 | 2008-11-06 | Combinatorx, Incorporated | Methods and compositions for the treatment of neurodegenerative disorders |
| WO2009133128A1 (en) * | 2008-04-29 | 2009-11-05 | Pharnext | Combination compositions for treating alzheimer disease and related disorders with zonisamide and acamprosate |
| EP2282779B1 (en) * | 2008-04-29 | 2013-03-13 | Pharnext | New therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response |
| JP5721230B2 (ja) * | 2008-04-29 | 2015-05-20 | ファーネクストＰｈａｒｎｅｘｔ | 血管新生の調節を通したアルツハイマー病および関連障害の処置のための新たな治療アプローチ |
| EP2429530B1 (en) * | 2009-05-14 | 2018-11-07 | The General Hospital Corporation | (s)-meclizine for treating ischaemia-reperfusion injury |
-
2010
- 2010-12-10 DE DE102010062810.7A patent/DE102010062810B4/de not_active Expired - Fee Related
-
2011
- 2011-08-30 RU RU2016118021A patent/RU2016118021A/ru not_active Application Discontinuation
- 2011-08-30 DK DK13190419.5T patent/DK2693216T3/en active
- 2011-08-30 BR BR112013005472-7A patent/BR112013005472A2/pt not_active Application Discontinuation
- 2011-08-30 EP EP11755294.3A patent/EP2614060B1/de active Active
- 2011-08-30 PL PL11755294T patent/PL2614060T3/pl unknown
- 2011-08-30 EP EP16180106.3A patent/EP3097914A3/de not_active Withdrawn
- 2011-08-30 DK DK11755294.3T patent/DK2614060T3/da active
- 2011-08-30 ES ES11755294.3T patent/ES2605705T3/es active Active
- 2011-08-30 RU RU2013110018/04A patent/RU2587154C2/ru active
- 2011-08-30 CN CN201180053670.4A patent/CN103237802B/zh active Active
- 2011-08-30 WO PCT/EP2011/064893 patent/WO2012031941A2/de not_active Ceased
- 2011-08-30 ES ES13190419T patent/ES2701453T3/es active Active
- 2011-08-30 CA CA2870626A patent/CA2870626C/en active Active
- 2011-08-30 EP EP13190419.5A patent/EP2693216B1/de active Active
- 2011-08-30 MX MX2013002612A patent/MX357521B/es active IP Right Grant
- 2011-08-30 DE DE102011053114A patent/DE102011053114A1/de not_active Ceased
- 2011-08-30 PL PL13190419T patent/PL2693216T3/pl unknown
- 2011-08-30 CA CA2811454A patent/CA2811454C/en active Active
- 2011-08-30 JP JP2013527544A patent/JP6084924B2/ja active Active
- 2011-08-30 CN CN201610631393.5A patent/CN106243060A/zh active Pending
- 2011-08-30 US US13/821,515 patent/US20130184268A1/en not_active Abandoned
-
2014
- 2014-09-29 US US14/499,918 patent/US9370523B2/en active Active
-
2015
- 2015-09-08 US US14/847,089 patent/US20150374711A1/en not_active Abandoned
-
2016
- 2016-07-01 JP JP2016131781A patent/JP6426663B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201205219B (en) | Method for diagnosing the stsate of health of a battery | |
| ZA201209730B (en) | Method for increasing the health of a plant | |
| SG184797A1 (en) | Q tomography method | |
| GB201001833D0 (en) | Method | |
| GB201007353D0 (en) | Method | |
| GB201007354D0 (en) | Method | |
| GB201004759D0 (en) | Method | |
| GB201011513D0 (en) | Method | |
| GB201008541D0 (en) | Diagnostic methods | |
| GB2513948B (en) | Attachment method | |
| GB201011420D0 (en) | Method for diagnosis | |
| GB201008719D0 (en) | Diagnostic method | |
| GB201006306D0 (en) | Method | |
| GB201016161D0 (en) | Diagnostic method | |
| AP2013007084A0 (en) | Diagnostic method | |
| GB201012148D0 (en) | Method | |
| GB201100223D0 (en) | Diagnostic method | |
| PL2693216T3 (pl) | Sposób diagnozowania lub wstępnego diagnozowania beta-amyloidopatii | |
| ZA201301498B (en) | Diagnostic method | |
| GB201012784D0 (en) | Method | |
| GB201010855D0 (en) | Method | |
| IL229375A0 (en) | A method for diagnosing rheumatoid arthritis | |
| GB201007207D0 (en) | Method | |
| GB201007522D0 (en) | Method | |
| GB201002732D0 (en) | Novel diagnostic method |